Pradaxa (dabigatran etexilate mesylate), a new oral anticoagulant, achieved Food & Drug Administration (“FDA”) approval on October 19, 2010. One notable advantage of using Pradaxa to replace Warfarin to prevent clot formation is the elimination of INR testing in patients taking Pradaxa. INR is the acronym for International Normalized Ratio, which is used to monitor the effectiveness of anticoagulant such as warfarin.
Free Consultation Today
800-780-8607
Review Us
Our Fee Promise:
No Recovery? No Fee.
- Actos
- Announcement
- Articles
- Aviation Disasters
- Bike Accidents
- Boating Accidents
- Car Accidents
- Cases
- Commercial Litigation
- Common Questions
- Corporate Fraud
- Defective Design
- Defective Drugs
- Defective Medical Devices
- Do You Know?
- Environmental Disasters
- General
- Golf Cart Accidents
- Hot Topics
- Intellectual Property
- Law Technology
- Mass Tort News
- Mass Torts
- Medical Malpractice
- Miscellaneous
- Motorcycle Accidents
- Personal Injury
- Politics and Topical News
- Pradaxa
- Premises Liability
- Product Defect
- Product Liability
- Professional Liability
- Railroad Disasters
- Rejuvenate/ABG II
- Sexual Assault
- Slip and Fall
- Transvaginal Mesh
- Trucking Accidents
- Wrongful Death
View Our Brochure